drugset / Trial / NCT00453271

Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail

NCT00453271

Phase 2 Completed 443 enrolled NanoBio Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to determine whether NB002, 0.25%, and 0.5% are safe and effective in the treatment of distal subungual onychomycosis of the toenail.

Timeline

Start
2007-01
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetylpyridinium Small molecule 0.25 %
Subject Cetylpyridinium Small molecule 0.5 %

Indications